Management of Antiphospholipid Syndrome in Pregnancy

2014 ◽  
pp. 194-201
1994 ◽  
Vol 160 (4) ◽  
pp. 217-218
Author(s):  
Frank L Clark ◽  
Peter Greenwood ◽  
Peter J G Forster

10.5772/33222 ◽  
2012 ◽  
Author(s):  
Kjell Haram ◽  
Eva-Marie Jacobsen ◽  
Per Morten

2006 ◽  
pp. 555-567
Author(s):  
Lorin Lakasing ◽  
Susan Bewley ◽  
Catherine Nelson-Piercy

Author(s):  
Aida Kalok ◽  
Rizna Abdul Cader ◽  
Ima Indirayani ◽  
Abdul Kadir Abdul Karim ◽  
Shamsul Azhar Shah ◽  
...  

Abstract Background Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory condition with multi-organ involvement predominantly affecting young women. There are very limited studies in pregnancy in Asian SLE patients and therefore we embarked on this study to identify pregnancy outcomes of Malaysian women with SLE. Materials and methods We performed a retrospective study of pregnancy outcomes in SLE patients in our institution from January 2007 to December 2014. A total of 71 pregnancies from 44 women were analysed. Results The mean age of our cohort was 30.5 ± 3.9 years. The rate of active disease at conception, antiphospholipid syndrome and lupus nephritis were 22.5%, 32.4% and 57.7% respectively. SLE flare occurred in 33 out of 71 pregnancies whereas 19 pregnancies were complicated with preeclampsia. The livebirth rate for our cohort was 78.9%, whilst preterm delivery was 42.9%. On univariate analysis, active disease and flare in pregnancy were both strongly associated with foetal loss and preterm delivery. Lupus nephritis (p = 0.011), SLE flare (p = 0.008) and antiphospholipid syndrome (p = 0.032) significantly increased the risk of preeclampsia. Aspirin and hydroxychloroquine were protective against foetal loss [odds ratio (OR) 0.12] and preeclampsia (OR 0.25), respectively. On multivariate analysis, active disease was a predictor of SLE flare (p = 0.002) and foetal loss (p = 0.018) and SLE flare was the main predictor of preterm delivery (p = 0.006). Conclusions Pregnancies in women with SLE should be planned and aspirin and HCQ use were beneficial in reducing adverse pregnancy outcomes.


2002 ◽  
Vol 100 (6) ◽  
pp. 1354 ◽  
Author(s):  
Raj Rai ◽  
Lesley Regan

2002 ◽  
Vol 100 (3) ◽  
pp. 408-413 ◽  
Author(s):  
Roy G. Farquharson ◽  
Siobhan Quenby ◽  
Michael Greaves

2019 ◽  
Vol 9 (4) ◽  
pp. 37-42
Author(s):  
Thaís da Silva Santos ◽  
Izabel Galhardo Demarchi ◽  
Tatiane França Perles Mello ◽  
Jorge Juarez Vieira Teixeira ◽  
Maria Valdrinez Campana Lonardoni

Antiphospholipid syndrome (APS) was characterized as an autoimmune condition with the production of antiphospholipid antibodies (aPL) associated with thrombosis and morbidity in pregnancy. The prevalence of aPL in the population ranges from 1% to 5% in patients with APS. The hypotheses regarding pathophysiological mechanisms are strongly related to binding proteins and antiphospholipid antibodies. The exact mechanisms by which they lead to clinical manifestations appear to be heterogeneous, but it is believed which aPL contribute to the cellular activation/coagulation, and so cause the thrombotic events. The treatment of APS should be an individual character and several factors should be taken into accounts, such as a number of antibodies, the age of the patient and the history of thrombotic events.


Sign in / Sign up

Export Citation Format

Share Document